Related Experiment Video
Updated: Jul 11, 2026
Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Plasminogen activator inhibitor-1 in vascular thrombosis
Randal J Westrick1, Daniel T Eitzman
1Department of Human Genetics, University of Michigan Medical Center, and the Ann Arbor Veterans Administration Hospital, Ann Arbor, Michigan, USA.
Insights
Targeting plasminogen activator inhibitor-1 (PAI-1) may offer a novel treatment for thrombosis. Inhibiting PAI-1 could reduce occlusive thrombosis in high-risk patients, with minimal bleeding risk.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Thrombotic complications of vascular disease are a leading cause of death.
- Current therapies for vascular thrombosis are limited.
- Obesity, diabetes, and metabolic syndrome increase thrombotic risk.
Purpose of the Study:
- To evaluate the potential of targeting plasminogen activator inhibitor-1 (PAI-1) for treating vascular thrombosis.
- To assess the safety and efficacy of PAI-1 inhibition in preclinical models and consider clinical application.
Main Methods:
- Review of animal models demonstrating PAI-1 inhibition attenuates thrombosis.
- Analysis of human studies on PAI-1 deficiency and bleeding risk.
- Identification of patient populations at high risk for vascular events.
Main Results:
- PAI-1 inhibition effectively reduces arterial and venous occlusive thrombosis in animal models.
- Complete PAI-1 deficiency is associated with rare spontaneous bleeding complications in animal and human studies.
- Elevated PAI-1 levels are observed in patients with obesity, diabetes, and metabolic syndrome.
Conclusions:
- Targeting PAI-1 represents a promising strategy for enhancing endogenous fibrinolysis and preventing thrombosis.
- PAI-1 inhibition may be a safe and effective treatment for patients at high risk of vascular events.
- Clinical trials are warranted to test the effectiveness of PAI-1 inhibition in at-risk patient populations.
Abstract:
Thrombotic complications of vascular disease constitute the leading cause of morbidity and mortality in much of the developed world. Current drug therapies available to treat the thrombotic component of arterial and venous vascular complications remain limited. Novel safe and effective treatment strategies to reduce formation of occlusive thrombosis will likely have a major impact on reducing the economic burden of vascular disease on the healthcare system. Enhancing endogenous fibrinolysis by targeting plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of circulating plasminogen activators, has been shown to be effective in markedly attenuating the formation of arterial and venous occlusive thrombosis in animal models. In addition, animal and human studies of PAI-1 deficiency indicate that spontaneous bleeding complications associated with even complete PAI-1 deficiency would be rare. Patients most likely to benefit from PAI-1 inhibition would be those at high risk for vascular events where PAI-1 is elevated, such as is observed in obesity, diabetes and the metabolic syndrome. Since obesity and metabolic syndrome are now epidemic, and will likely have a major adverse impact on vascular thrombotic events, it may be time to test the clinical effectiveness of PAI-1 inhibition in a patient population at high risk for vascular thrombosis.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:16Clot Retraction and Fibrinolysis
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis I: Introduction